quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:30:00·80d
NEWSRelease
MIRA Pharmaceuticals Inc. logo

MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study

MIRA· MIRA Pharmaceuticals Inc.
Health Care
Original source

Companies

  • MIRA
    MIRA Pharmaceuticals Inc.
    Health Care

Related

  • INSIDER22d
    SEC Form 4 filed by Aminov Erez
  • SEC23d
    SEC Form 10-K filed by MIRA Pharmaceuticals Inc.
  • SEC32d
    MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events
  • NEWS32d
    MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies
  • NEWS51d
    MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2
  • SEC51d
    MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events
  • INSIDER65d
    Aminov Erez was granted 125,000 shares, exercised 613,595 shares at a strike of $0.96 and sold $1,294,685 worth of shares (613,595 units at $2.11), increasing direct ownership by 4% to 3,592,666 units (SEC Form 5)
  • SEC80d
    MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022